Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRaincy Montfermeil Hospital Group

About this trial

Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.

Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation.

This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome.

Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 18 years and older

Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months

Patient is motivated to participate in the Adapted Physical Activity (APA) program

Medical certificate confirming fitness to engage in remote physical activity

Disqualifiers

Patients under 18 years of age

Medical contraindication to physical activity

Total >1500 MET-min/week of vigorous activity on at least 3 days, OR

Total physical activity >3000 MET-min/week, regardless of distribution

Trial design

Design model

Single group

Treatments tested in this trial

  • adapted physical activity

    Procedure/Surgery

    Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application

Treatment groups

72 Participants
are divided into 1 treatment group
Group A: Pre- and post-intervention comparison following participation in the Adapted Physical Activity (APA)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Impact of a Remote Adapted Physical Activity Program Delivered via the MOOV+ Application on Quality of Life in Patients With Inflammatory Bowel Disease: A Pilot Before-and-After Study

Change in total Inflammatory Bowel Disease Questionnaire (IBDQ-32) score between baseline and the end of the program at Month 3 (M3)

Time frame
From baseline (Month 0) to Month 3

Secondary outcomes

1

evaluate the effect of the program on the different subdomains of health-related quality of life, including bowel symptoms, systemic symptoms, emotional function, and social function

Variation in the four IBDQ-32 subscale scores between baseline (Month 0) and the end of the program (Month 3)

Time frame
From baseline (Month 0) to Month 3
2

Assess the feasibility of the Remote Adapted Physical Activity Program

Variation of participation rate (number of enrolled patients / number of eligible patients)

Time frame
From baseline (Month 0) to Month 3
3

Assess the feasibility of the of the Remote Adapted Physical Activity Program

Adherence to the program measured by session attendance rate (sessions attended / sessions scheduled) and dropout rate (number and reasons for early withdrawal).

Time frame
From baseline (Month 0) to Month 3
4

impact of APA on psychological status

HADS score

Time frame
From baseline (Month 0) to Month 3

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Raincy Montfermeil Hospital Group

Lead sponsor

Janssen Cilag S.A.S.

Collaborator